Table 1.
Demographic and prescription data of tolerability cohort by CYP2C19 phenotype.
| Parameter | Total n = 248 | PM n = 5 (2%) | IM n = 57 (23%) | NM n = 100 (40%) | RM n = 73 (29%) | UM n = 13 (5%) |
|---|---|---|---|---|---|---|
| Age (years) Average (range) | 14.4 (6.4–18.8) | 13.9 (12.1–15.3) | 14.4 (6.8–18.9) | 14.6 (7.8–18.5) | 14.2 (6.4–18.6) | 14.8 (12.0–17.7) |
| <12 (n, %) | 27 (11%) | – | 7 (12%) | 8 (8%) | 12 (16%) | – |
| ≥12 (n, %) | 221 (89%) | 5 (100%) | 50 (88%) | 92 (92%) | 61 (84) | 13 (100%) |
| Diagnosis | ||||||
| Anxiety (n, %) | 30 (12%) | 1 (20%) | 5 (9%) | 13 (13%) | 11 (15%) | – |
| Depressive (n, %) | 68 (27%) | – | 19 (33%) | 25 (25%) | 16 (22%) | 8 (62%) |
| Anxiety+Depressive (n, %) | 150 (61%) | 4 (80%) | 33 (58%) | 62 (62%) | 46 (63%) | 5 (38%) |
| Sex | ||||||
| Female (n, %) | 162 (65%) | 3 (60%) | 41 (72%) | 63 (63%) | 47 (64%) | 8 (62%) |
| Male (n, %) | 86 (35%) | 2 (40%) | 16 (28%) | 37 (37%) | 26 (36%) | 5 (38%) |
| Race | ||||||
| Black (n, %) | 23 (9%) | 0 (0%) | 7 (12%) | 7 (7%) | 7 (10%) | 2 (15%) |
| Other (n, %) | 25 (10%) | 2 (40%) | 7 (12%) | 11 (11%) | 4 (5%) | 1 (8%) |
| White (n, %) | 200 (81%) | 3 (60%) | 43 (76%) | 82 (82%) | 62 (85%) | 10 (77%) |
| Es/citalopram prescriptions n (%) | ||||||
| Only escitalopram | 197 (79%) | 4 (80%) | 46 (81%) | 79 (79%) | 56 (77%) | 12 (92%) |
| Only citalopram | 38 (15%) | 1 (20%) | 6 (11%) | 16 (16%) | 14 (19%) | 1 (8%) |
| Both | 13 (5%) | 0 | 5 (9%) | 5 (5%) | 3 (4%) | 0 |
| Total time on es/citalopram (days) Median (range) | 236 (1–1974) | 137 (35–453) | 240 (1–1974) | 271.5 (5–1424) | 231 (1–1589) | 171 (20–462) |
| # of concomitant medications Median (range) | 2 (0–11) | 2 (1–5) | 2 (0–11) | 2 (0–11) | 1 (0–8) | 2 (0–4) |
| Concomitant omeprazole n (%) | 22 (9%) | 1 (20%) | 5 (9%) | 6 (6%) | 7 (10%) | 3 (30%) |
| Concomitant oral contraceptives n (%) | 24 (10%) | 0 (0%) | 7 (12%) | 12 (12%) | 4 (5%) | 1 (8%) |
| Adherence concerns (n, %) | 26 (10%) | 0 (0%) | 8 (14%) | 12 (12%) | 3 (4%) | 3 (23%) |
| Maximum dose (mg) Median (range) | 15 (2.5–40) | 15 (5–35) | 15 (2.5–40) | 17.5 (2.5–40) | 15 (2.5–40) | 20 (5–20) |
n, number; mg, milligrams; PM, poor metabolizer; IM, intermediate metabolizer; NM, normal metabolizer; RM, rapid metabolizer; UM, ultrarapid metabolizer.